Valuation : BICO Group AB

Market Cap 1.41B 148M 127M 119M 109M 205M 14.12B 206M 550M 7.12B 555M 543M 23.56B P/E 2026 *
-6.19x
P/E 2027 * -11.1x
Enterprise Value 1.34B 141M 121M 113M 103M 195M 13.43B 195M 523M 6.77B 528M 517M 22.4B EV / Sales 2026 *
0.83x
EV / Sales 2027 * 0.74x
Free-Float
69.88%
Yield 2026 *
-
Yield 2027 * -
1 day-26.24%
3 months-28.23%
6 months-1.65%
Current year-33.61%
Current year 0.35
Extreme 0.35
0.65
1 year 0.35
Extreme 0.35
0.75
3 years 0.35
Extreme 0.35
1.55
5 years 0.35
Extreme 0.35
14.8
10 years 0.35
Extreme 0.35
14.8
Manager TitleAgeSince
Chief Executive Officer 54 2023-11-26
Director of Finance/CFO 56 2026-02-28
Chief Operating Officer - 2026-01-06
Director TitleAgeSince
Director/Board Member 70 2019-12-17
Director/Board Member 37 2015-02-28
Director/Board Member - 2026-05-06
Change 5-day change 1-year change 3-year change Capi.($)
-26.24%-.--% - - 147M
-0.47%+0.50%+29.21%+16.45% 234B
+0.15%-0.11%+5.21%-15.60% 151B
-0.90%-1.98%-22.09%+23.36% 131B
-3.11%-5.47%-55.92%-8.06% 69.81B
-0.91%+0.13%+11.19%+18.09% 52.33B
0.00%-1.38%-16.80%-13.58% 50.91B
+1.68%+0.89%+32.86%+31.76% 43.8B
+1.71%+4.09%+42.98%+54.10% 40.69B
+0.03%+3.20%-16.39%+46.45% 34B
Average -2.25%-0.44%+1.14%+17.00% 89.79B
Weighted average by Cap. +0.07%-0.57%+3.96%+11.65%

Financials

2026 *2027 *
Net sales 1.62B 170M 146M 137M 125M 236M 16.28B 237M 634M 8.2B 640M 626M 27.15B 1.69B 177M 152M 142M 130M 246M 16.92B 246M 659M 8.53B 665M 651M 28.22B
Net income -227M -23.85M -20.48M -19.17M -17.55M -33.07M -2.28B -33.16M -88.74M -1.15B -89.56M -87.62M -3.8B -126M -13.24M -11.37M -10.64M -9.74M -18.35M -1.26B -18.41M -49.26M -637M -49.71M -48.64M -2.11B
Net Debt -69M -7.25M -6.22M -5.83M -5.34M -10.05M -692M -10.08M -26.97M -349M -27.22M -26.63M -1.16B -166M -17.44M -14.97M -14.02M -12.84M -24.18M -1.67B -24.25M -64.89M -840M -65.49M -64.08M -2.78B
Logo BICO Group AB
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Employees
554
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
19.94SEK
Average target price
29.00SEK
Spread / Average Target
+45.44%

Quarterly revenue - Rate of surprise